Analysts’ Recent Ratings Updates for Encompass Health (EHC)

Several brokerages have updated their recommendations and price targets on shares of Encompass Health (NYSE: EHC) in the last few weeks:

• 8/16/2026 – Encompass Health was upgraded by Wall Street Zen from “hold” to “buy”.
• 8/12/2026 – Encompass Health was upgraded by Weiss Ratings from “hold (c+)” to “buy (b-)”.
• 8/10/2026 – Encompass Health had its price target raised by TD Cowen from $125.00 to $140.00. They now have a “buy” rating on the stock.
• 8/8/2026 – Encompass Health was downgraded by Wall Street Zen from “buy” to “hold”.
• 8/7/2026 – Encompass Health had its price target raised by UBS Group AG from $150.00 to $155.00. They now have a “buy” rating on the stock.
• 8/7/2026 – Encompass Health had its price target raised by Truist Financial Corporation from $140.00 to $150.00. They now have a “buy” rating on the stock.
• 8/6/2026 – Encompass Health had its price target raised by Barclays PLC from $140.00 to $144.00. They now have an “overweight” rating on the stock.
• 6/26/2026 – Encompass Health was downgraded by Weiss Ratings from “buy (b-)” to “hold (c+)”.

Encompass Health Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, October 15th. Stockholders of record on Thursday, October 1st will be paid a dividend of $0.21 per share. This is a boost from Encompass Health’s previous quarterly dividend of $0.19. The ex-dividend date of this dividend is Thursday, October 1st. This represents a $0.84 dividend on an annualized basis and a dividend yield of 0.7%. Encompass Health’s dividend payout ratio is currently 12.38%.

Insider Transactions at Encompass Health

In other Encompass Health news, CEO Mark J. Tarr sold 173,148 shares of the company’s stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.47, for a total transaction of $21,724,879.56. Following the transaction, the chief executive officer directly owned 267,814 shares in the company, valued at approximately $33,602,622.58. This represents a 39.27% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Also, EVP John Patrick Darby sold 8,906 shares of the stock in a transaction dated Monday, August 10th. The shares were sold at an average price of $125.95, for a total transaction of $1,121,710.70. Following the completion of the transaction, the executive vice president directly owned 75,041 shares of the company’s stock, valued at approximately $9,451,413.95. This trade represents a 10.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Company insiders own 1.80% of the company’s stock.

Encompass Health Corporation is a leading provider of post?acute healthcare services in the United States, operating a comprehensive network of inpatient rehabilitation hospitals and home health and hospice agencies. Its inpatient rehabilitation hospitals offer intensive therapy programs for patients recovering from conditions such as stroke, brain injury, spinal cord injury, cardiac and pulmonary disorders, and orthopedic procedures. Through its home health segment, Encompass Health delivers skilled nursing, physical therapy, occupational therapy and speech therapy to patients in the comfort of their homes, while its hospice services provide end?of?life care focused on symptom management and emotional support for patients and families.

Founded in 1984 as HealthSouth Corporation and rebranded as Encompass Health in 2018, the company has grown organically and through acquisitions to serve patients across more than 30 states.